Entremed Inc About
Entremed EntreMed is a clinical-stage pharmaceutical company
focused on developing the next generation of multi-mechanism oncology and anti-inflammatory
drugs which directly target disease cells and the blood vessels that nourish them.
Panzem® (2-methoxyestradiol
or 2ME2),is the Company’s lead drug candidate, and is currently in clinical trials
for cancer. EntreMed
compounds work through multiple mechanisms of action (MOA) e.g., 2ME2’s MOAs include
the inhibition of 1) angiogenesis,
2) microtubule formation, 3) hypoxia inducible factor-1 alpha (HIF-1a) and 4)
osteoclastic activity (bone resorption), as well as 5) the induction of apoptosis.
EntreMed’s goal is to develop and commercialize new compounds based
on the Company’s expertise in the science of angiogenesis,
cell cycle regulation and inflammation
-- processes vital to the treatment of cancer and other diseases. Entremed has
identified several new molecules, including analogs of 2ME2, modulators of fibroblast
growth factor-2 (FGF-2) activity, tissue factor pathway inhibitor (TFPI) peptides,
and proteinase activated receptor-2 (PAR-2) antagonists. Panzem Capsules Panzem Preclinical
Trials: NCD 2ME2 (2-Methoxyestradiol) --Analogs of 2ME2 ---ENMD
0996 (FGF-2 Cancer Vaccine) ---Tissue Factor Pathway Inhibitors (TFPI)
---Proteinase Activated Receptor-2 (PAR-2) Inhibitors More
on Entremed